The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Cancer statistics in China, 2015

Wanqing Chen, Rongshou Zheng, Peter D. Baade et al. · CA A Cancer Journal for Clinicians · 2016 · 18K citations · Full text

Medicine, Oncology, Population Health Sciences +17

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

Jin Li, Shukui Qin, Jianming Xu et al. · Journal of Clinical Oncology · 2016 · 997 citations

Medicine, Oncology, Pharmacology +15

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study

Giovanni Grignani, Emanuela Palmerini, Palma Dileo et al. · Annals of Oncology · 2011 · 356 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

Florence Duffaud, Olivier Mir, Pascaline Boudou‐Rouquette et al. · The Lancet Oncology · 2018 · 316 citations

Medicine, Oncology, Pharmacology +13